Goal 3: Advance Translational Research

To facilitate innovation and accelerate research translation, knowledge dissemination, and implementation science that enhances public health.

Goal 3: Advance Translational Research

Submitted by (@societyforvascularsurgery)

Cohort studies and clinical trials in vascular disease

Utilization of well characterized cohort studies and clinical trials to conduct ancillary scientific studies on pathophysiology, responses to treatment, and identify new ways to predict and treat disease. Restore the Ancillary Studies mechanism. Improved biobanks and data sharing platforms are needed. Facilitate public-private partnerships.

Voting

2 net votes
3 up votes
1 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

A Pipeline for Investigator- Initiated Translational Science

How might the NHLBI effectively encourage and support its investigators to collaborate with strategic partners to pursue the early translation of their HLBS discoveries into new diagnostics and therapeutics? The critical challenges to effective early translation of discovery science experienced by the investigator community include: 1. The need for translational skills development, training and guidance 2. Need for ...more »

Voting

196 net votes
226 up votes
30 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator1)

Enhancing Cardiovascular Health in Childhood Through Adulthood

To enhance or maintain ideal cardiovascular health (CVH) in children and adolescents, what novel and long-term interventions can be implemented using multi-level (i.e., targeting individual, family, community, and built environment) and sustainable approaches?

Would implementation and translation of the AHA 2020 impact goals in children and adolescents enhance their CVH through adulthood?

Voting

17 net votes
34 up votes
17 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@shahram.mori.md)

Should Allogeneic stem cell transplantation be considered as an upfront treatment in high risk double hit DLBCL?

Double-hit lymphomas (DHL’s) are high-grade B-cell lymphomas characterized by chromosomal rearrangements of MYC gene with BCL2 and less commonly, BCL6.Large analysis of patients with de novo DLBCL have shown that conventional chemotherapy does not improve the survival of DHL Aggressive upfront chemotherapy followed by autologous stem cell transplantation (ASCT) has become a standard treatment in eligible patients. Retrospective ...more »

Voting

2 net votes
3 up votes
1 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@k.willard)

Palliative and hospice care for COPD patients

Does palliative care and/or hospice care as practiced across communities improve end-of-life care for COPD – specifically, does it reduce the burden of symptoms, improve HRQoL and satisfaction, reduce utilization in last 6 months of life (i.e. hospital visits, cost, invasive ventilation use, etc), improve the end-of-life experience, and increase the concordance of place of death to expressed patient preferences?

Voting

12 net votes
16 up votes
4 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

Next generation of cellular blood products for clinical use

What advancements in our understanding of hematopoietic stem cell differentiation can be combined with practical developments in novel processing and storage technologies to develop the next generation of transfused blood therapeutics? There is a dearth of tools to evaluate the efficacy of transfused blood products, although this is the most commonly employed therapeutic procedure in the US. There is also no financial ...more »

Voting

-3 net votes
24 up votes
27 down votes
Active